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ABSTRACT 
Presbyopia occurs after 40 years of age in humans with a progressive loss of accommodation. 
Accommodation depends on the contraction of the ciliary muscle and iris, lens changes and convergence.  
The parasympathetic system regulates the degree of ciliary muscle and iris contraction necessary to modify 
the shape and position of the lens and its stimulation is effective through the activation of muscarinic 
receptors that are present in both structures. The hypothesis proposed here suggests the correction of 
accommodation in emmetropic presbyopic patients using a pharmacological treatment that includes a 
cholinergic agent combined with non-steroidal anti-inflammatory drugs (NSAIDs). This drug combination 
can restore near vision without affecting distance vision. It is important to note that the pharmaceutical 
form used was devoid of any inflammatory or other collateral effects. 
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INTRODUCTION  
Presbyopia is the progressive loss of accommodation resulting 
in loss of the visual ability to focus on objects located at 
different distances. Accommodation in humans is performed by 
ciliary muscle and iris sphincter contractions, convergence and 
changes in the shape and position of the lens [1,2]. The latter 
action is passive, meaning that the lens changes are dependent 
on the ciliary muscle and iris contractions. Also, when the 
centre of the accommodation is active, the ciliary muscle 
contraction is stimulated and miosis and convergence occurs in 
normal binocular patients [2,3].  
The iris and ciliary muscle have muscarinic receptors that are 
stimulated by the parasympathetic system through its 
cholinergic neurotransmitter acetylcholine [4]. This stimulation 
produces contraction of the ciliary muscle and changes in pupil 
size by changing the shape and position of the lens, and 
consequently provokes accommodative capacity related to the 
parasympathetic activity [5-7]. As presbyopia has been 
corrected from the thirteenth century with glasses, and since 
the last century with contact lenses and surgery [8,9], a 
pharmacological treatment to restore accommodation is 
proposed here. 
 
HYPOTHESIS 
It is well known that when parasympathetic stimulation takes 
place with pilocarpine, the generation of ciliary muscle 
spasmodic contraction occurs and lens thickness increases, 
which in turn increases the focus depth [7,10]. This situation 
improves near vision but decreases distance vision because the 
lens cannot change its thickness or position [6,11]. Combining 
NSAIDs with parasympathetic agonists, the intensity of the 
contraction of the pupil [12] and the ciliary muscle was 
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decreased, allowing the lens to change shape and position for 
good vision at all distances. 
The combination with NSAIDs eliminates local inflammation 
that always appears as secondary to the chronic stimulation of 
pilocarpine (fixed pupil, posterior synechiae and pigment 
dispersion) [12].  
In this sense, the hypothesis aims to resolve accommodation in 
emmetropic presbyopic patients using a pharmacological 
treatment, as described above, through parasympathetic 
stimulation combined with NSAIDs. 
 
DISCUSSION 
According to the hypothesis criteria, work has been performed 
for a decade on muscarinic stimulation with carbachol, 
pilocarpine and physostigmine, an anticholinesterase inhibitor. 
In all cases, near vision was restored with more or less success 
according to the quality and concentration of the stimulating 
agent. A loss of far and half distance vision in all patients 
treated was observed [2,11]. However, chronic stimulation with 
any of these drugs caused an inflammatory reaction of the 
anterior uvea. When a non-steroidal anti-inflammatory 
(diclofenac) was added to the parasympathetic agonist 
pilocarpine the pharmacological combination restored near 
vision without causing blurred far and half distance vision or 
inflammatory reactions. If the combination of the 
parasympathetic agonist with a steroidal anti-inflammatory 
(dexamethasone) was used, an inflammatory reaction was 
prevented. It was also observed that near vision was restored, 
but blurred far and half distance vision was noticed. Therefore, 
a clinical benefit was observed in the patients treated with a 
combination of pilocarpine and diclofenac. 
The uveal tract chronic stimulation using the 
parasympathomimetic agent caused inflammatory reactions, 
pigment dispersion, posterior synechiae and spasmodic 
contractions of the ciliary muscle and iris, which resulted in a 
fixed pupil and myopic shift [11,13]. 
The NSAIDs, which are able to inhibit cyclooxygenase(s) activity, 
act as anti-inflammatory agents in the anterior uveal tract, 
decreasing miosis and spasmodic ciliary contractions, pigment 
dispersion and posterior synechia, because they diminish the 
local inflammation caused by the chronic instillation of 
parasympathomimetic drugs [12,14,15]. 
In this sense, it was found that the combination of pilocarpine 
with diclofenac was the most effective formula that could be 
used chronically for the treatment of presbyopia without the 
occurrence of side-effects (pilocarpine 1% and 0.1% diclofenac, 
[1% pilocarpina Poen, Poen, Buenos Aires, Argentina. Voltaren 
0.1%, Novartis, Buenos Aires, Argentina] at 6 hour intervals 
during the daily hours). Within the 100 subjects treated, 20 
patients presented ocular burning and discomfort right after 
drop instillation and only one of them abandoned treatment for 
these cause. The others four patients who deserted 
pharmacological treatment were fearful to the chronically drop 
instillation. 
Two hundred emmetropic eyes of 100 patients of both sexes 
with presbyopia, in the age range of 45 years to 50 years, were 
treated during a 5 year period. All of patients had a near vision 
of Jaeger 1 (J1) and a far vision of 20/20 with an eye drop 
instillation at 6 hour interval the daily hours. None had ocular 
or systemic diseases and 95% of the patients were under 
treatment. Moreover, 1% of the patients discontinued 
treatment for ocular burning and discomfort, while 4% 
preferred treatment with glasses. 
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Figure1.  Near vision accommodation in patients in the pharmacological 
treatment. Accommodation in near vision in 200 emmetropic eyes of 
100 patients treated with (▲ right eye) (▼ left eye) or without 
(without the drop for 24 hours) or with  the combination of pilocarpine 
and diclofenac (● right eye) (■ left eye), during a 5 year period.  
 
As shown in Figure 1, in the first year of treatment, the 
enhanced accommodation improved near vision and this 
improved vision was maintained for 5 years. Distance vision 
remained at 20/20 and was unchanged during the same period. 
The combination of a muscarinic cholinergic agonist and NSAIDs 
allowed the chronic use of topical treatment to restore 
accommodation with good near and far vision. 
 
CONCLUSION 
The restoration of accommodation can be achieved by 
stimulating ciliary muscle contractions with parasympathetic 
drug administration to modify the shape and position of the 
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lens. The studied pharmacological treatment showed that the 
decrease in accommodation in presbyopic patients could be 
restored using a combination of pilocarpine with diclofenac. 
The possibility of this pharmacological treatment opens a new 
therapeutic approach for presbyopic patients, allowing them 
good accommodation over time. It is possible that, in the 
future, new pharmacological treatments can also be used to 
treat other refractive problems that depend on 
accommodation. 
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